Title : Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Pub. Date : 2019 May 1

PMID : 30847464






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). osimertinib epidermal growth factor receptor Homo sapiens
2 BACKGROUND: Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). osimertinib epidermal growth factor receptor Homo sapiens